This issue’s rare disease section is bursting with articles spanning a range of topics within the sector. First up, Quotient Sciences consider orphan drug development and CRO/CDMO collaboration, specifically in paediatric rare diseases (
page 10), while ProPharma explores clinical trials for rare diseases and how these could be improved (
page 14). Alexion then tells us about the challenges facing rare disease treatment and the importance of patient-centricity (
page 20), and Veeva assesses how companies are overcoming challenges related to rare disease education, development and launch of new medicines (
page 22). Finally, Synaptix Bio tells us about the problems facing the treatment of rare diseases (
page 17).